Second Vintage of Global Asset-Backed 
Private Credit Fund Series Exceeds Fundraising Target

NEW YORK, Jan. 8, 2026 — Davidson Kempner Capital Management LP (“Davidson Kempner”), a global investment management firm, today announced the final close of its Davidson Kempner Income Fund II (“DK Income Fund II” or the “Fund”), the Firm’s global asset-backed private credit fund series, bringing aggregate capital commitments to the strategy (including related separate accounts) to over $1.1 billion.  

With a flexible and opportunistic mandate, DK Income Fund II is an asset-based lending, closed-end private credit fund focused on building a stable, income-producing credit portfolio across a range of sectors and geographies. Targeting sectors underpinned by secular, long-term trends and favorable industry and collateral dynamics, the Fund invests across structured residential, corporate, specialty finance and hard asset-backed loans, with a strong emphasis on downside protection. The Fund builds upon the track record of its approximately $750 million first vintage, DK Income Fund I, which has invested approximately $1.4 billion as of September 30, 2025.

“We believe that DK Income Fund II fills a niche demand for diversified private credit exposure and enables us to take advantage of the diverse, global opportunity set in the current market environment,” said Tony Yoseloff, Managing Partner and Chief Investment Officer at Davidson Kempner. “In our view, the Fund’s structure and flexible mandate allows us to be highly selective, pursuing opportunities that focus on a stable return profile combined with significant upside potential for our investors.”

Mr. Yoseloff continued, “This is a strong fundraising outcome for our global asset-backed private credit fund series.  We view the positive outcome as a testament to our global sourcing network, local market knowledge, flexible solutions and reputation as a trusted counterparty in the marketplace.”

DK Income Fund II is co-managed by Mr. Yoseloff, Patrick Dennis, Co-Deputy Managing Partner, and Chris Krishanthan, Partner and Head of European and Asian Corporates, who have worked together for over 15 years. They are supported by a global team of investment professionals with deep experience in structured products, corporates and real estate across the U.S., Europe and Asia.

“Building on the success of our first Income Fund, we are pleased to announce the final close of DK Income Fund II, which could not have been accomplished without leveraging the knowledge, experiences and resources of our global team,” said Mr. Dennis. “We are now committed to using our strong, extensive sourcing platform to identify compelling investment opportunities in our core areas of focus.”

“The successful close of this Fund underscores the growing demand for tailored credit solutions amongst differentiated borrowers,” said Mr. Krishanthan. “We believe we are well positioned within this current environment to support different borrower needs through thoughtful sourcing, credit underwriting and structuring.”

About Davidson Kempner Capital Management

Davidson Kempner Capital Management LP is a global investment management firm with over 40 years of experience and a focus on fundamental investing with a multi-strategy approach. Davidson Kempner has more than $37 billion in assets under management and around 500 employees across eight offices: New York, Philadelphia, London, Dublin, Hong Kong, Shenzhen, Mumbai and Abu Dhabi. Additional information is available at: www.davidsonkempner.com. 

Media Contact
[email protected]

SOURCE Davidson Kempner

Proven to Reduce Preterm Births, NICU Admissions, and Costs, Pomelo Now Covers Nearly 7% of U.S. Births and Is Expanding to Deliver Evidence-Based Care for Women and Children Across Every Stage of Life

NEW YORK, Jan. 8, 2026 — Today, Pomelo Care, the national leader in evidence-based healthcare for women and children, announced it has raised $92 million in Series C funding led by Stripes with participation from Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel. Valued at $1.7 billion, Pomelo enters its next chapter after proving that its virtual maternity care model measurably reduces preterm births, NICU admissions, and medical costs at scale. Now supporting nearly 7% of all U.S. births, the company is expanding beyond maternity to bring its proven model to women and children throughout their lives—closing gaps in access and quality, lowering costs, and setting a new national standard for women’s and children’s healthcare.

“Pomelo Care was founded to measurably improve maternal health in the United States,” said Marta Bralic Kerns, founder & CEO of Pomelo Care. “We’ve demonstrated that when care is proactive, evidence-based, and accountable, we improve outcomes and costs come down. Now, with this funding, we’re taking that proven model beyond maternity to build a system of care that supports women and children throughout their lives, delivering better results across the entire healthcare ecosystem—for patients, payers, providers, and employers alike.”

Founded in 2021, Pomelo Care has delivered women’s and children’s healthcare that improves outcomes and lowers costs nationwide. Partnering with leading health plans and employers and now covering more than 25 million lives, Pomelo delivers 24/7 virtual care through a multispecialty clinical team powered by data science to identify risks early, monitor continuously, and close critical gaps. As provider burnout intensifies and care deserts spread, Pomelo has filled the gaps with coordinated care for patients as a trusted peer to practices, delivering quality medical care in collaboration with in-person providers.

• Clinical Outcomes & Accountability: Pomelo sets a new standard for accountability by publishing and presenting peer-reviewed, claims-based outcomes at leading national scientific and medical conferences, demonstrating results at scale, including:
  • 6.8-day reduction in NICU length of stay (16.3 days for complex cases)
  • 37% reduction in preterm births
  • 46% reduction in emergency room utilization
  • 718% higher prenatal depression screening and follow-up rates
• ROI: Engagement with Pomelo is associated with significant reductions in total cost of care for mothers and infants, resulting in a 3-5x ROI for customers. Reductions in preterm births, emergency visits, and NICU stays, three of the most expensive drivers of medical spend, demonstrate Pomelo’s ability to deliver durable savings at scale.
• Technology: The foundation of Pomelo’s model is its intelligent care platform, which embeds evidence-based care pathways and predictive analytics directly into clinician workflows to surface risks early and update them dynamically as care journeys unfold. This technology enables Pomelo to provide truly proactive care: identifying emerging issues before they escalate and ensuring patients receive timely, personalized care. The platform serves as a clinician co-pilot, providing patient insights, evidence-based playbooks, and recommended clinical actions within minutes, not days. For patients, the platform powers a seamless, supportive experience with 24/7 multimodal (phone, text, call, video, app) access to their multispecialty team of licensed clinicians, including nurses, dietitians, therapists, doulas, and providers who can diagnose, treat, and manage their care.

With this funding, Pomelo will continue to rapidly expand its proven maternity care model through partnerships with health plans and employers nationwide, while applying the same critical rigor, accountability, and accessibility to transform women’s and children’s health. From reproductive care, pregnancy, pediatrics, and hormonal health through perimenopause and menopause, to long-term preventive care and condition management, Pomelo is meaningfully empowering its patients while improving outcomes and reducing costs.

Pomelo recently launched a new program focused on midlife care, addressing the hormonal, metabolic, and mental health challenges women experience through perimenopause and menopause. The program provides comprehensive, evidence-based care to help women manage symptoms and improve overall well-being through preventive measures and chronic disease management. Results already show an 88% reduction in symptoms (Menopause Rating Scale) in 60 days, and 73% of patients reporting an increase in productivity after joining the program.

By continuing to innovate within maternity while extending the company’s evidence-based model to new stages of life, Pomelo is redefining the importance of clinical excellence at scale and setting a new national standard for women’s and children’s healthcare.

“We are thrilled to double down on our partnership with Pomelo and are proud to support Marta and the entire Pomelo team on their mission to build a category-leading business in women’s and children’s healthcare,” said Ron Shah, Partner at Stripes. “Pomelo has reached national scale at an unprecedented rate — now serving 25 million covered lives through Commercial and Medicaid health plan partnerships across the United States. The power of Pomelo’s amazing product is clear: exceptional patient satisfaction and strong clinical results showing meaningful reductions in pregnancy-related complications. We believe Pomelo’s intelligent care platform will power continued rapid growth and product expansion, meeting rising demand from patients and payers with a modern clinical experience and best-in-class operating metrics.”

About Pomelo Care

Pomelo Care is the national leader in evidence-based healthcare for women and children. We deliver personalized, high-quality clinical interventions from reproductive care and pregnancy, infant care and pediatrics, to hormonal health through perimenopause and menopause, with long-term preventive care and condition management. Our model delivers 24/7 multispecialty care to address the medical, behavioral, and social factors that most significantly impact outcomes for women and children. We partner with payers, employers, and providers to expand access to quality healthcare across the system. Learn more at pomelocare.com.

Media Contact
Julie Halpin
[email protected]

SOURCE Pomelo Care

Phase 2 data demonstrated 17.5-month median overall survival in advanced, chemo-refractory patients with microsatellite stable colorectal cancer (MSS-CRC)

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027

MODI’IN, Israel, Jan. 8, 2026 — KAHR Bio (KAHR or the Company), a clinical-stage biotechnology company developing DSP107, a first-in-class, bispecific 4-1BB–targeted, next-generation T-cell engager, today announced topline results from its Phase 2a dose-expansion cohort in late-line metastatic microsatellite stable colorectal cancer (MSS-CRC). DSP107 was evaluated in combination with atezolizumab (Tecentriq^®), an anti–PD-L1 therapy. The combination demonstrated favorable safety, clinical evidence of antitumor activity, and extended survival, including in patients with liver metastases.

KAHR also announced the closing of a $22 million round in equity financing. The equity investment was led by Flerie AB, Peregrine Ventures, Oriella Ltd. of the Consensus Business Group, aMoon Growth Fund, and the Cancer Focus Fund, with participation from certain additional existing investors and new investors including SPRIM Global Investments. The proceeds are expected to fully fund KAHR’s randomized, controlled Phase 2b trial of DSP107 in combination with atezolizumab versus fruquintinib (Fruzaqla^®) in fourth-line metastatic MSS-CRC. The trial was initiated in December 2025 following the U.S. Food and Drug Administration (FDA) investigational new drug (IND) clearance. In addition to the equity financing, KAHR has entered into a $10 million on-demand debt facility with SPRIM Global Investments, which the Company can draw down based on eligible research and development (R&D) activity under the Australian Government’s R&D tax rebate scheme. Additional equity commitments are under discussion as the Company continues to attract new investor interest.

The topline Phase 2a (NCT04440735) data demonstrated a median overall survival of 17.5 months, exceeding outcomes reported for currently approved therapies in this setting (6.4–10.8 months). Notably, approximately 75% of enrolled patients had liver metastases, a population historically refractory to immunotherapy. Across more than 130 patients treated with DSP107 to date in a variety of solid tumors and hematological malignancies, the therapy continues to demonstrate a favorable safety and tolerability profile.

Based on these encouraging results, KAHR has initiated a randomized, controlled, multicenter Phase 2b clinical trial in fourth-line metastatic, chemo-refractory MSS-CRC. The trial is expected to enroll at 18 sites across Australia and the United States, with the first patient having been enrolled in December 2025. Interim results are expected in late 2026, with topline data anticipated in the second half of 2027. Additional information about the study is available at clinicaltrials.gov (NCT07235293).

Anwaar Saeed, M.D., Chief of GI Oncology at the University of Pittsburgh and Co-Leader of the Cancer Therapeutics Program at UPMC Hillman Cancer Center, who co-led the Phase 2a trial said, “Observing efficacy with an immunotherapy approach in late line MSS-CRC patients with liver metastases is unexpected. DSP107’s mechanism is particularly suited to this setting as it utilizes CD47 overexpression on cancer cells to anchor a 4-1BB ligand to those cells, thereby attracting and activating T cells. CD47 expression increases in liver metastases following chemotherapy, creating a therapeutic window uniquely addressable by DSP107.”

“Following these compelling topline results demonstrating anti-tumor activity and meaningful survival outcomes in heavily pretreated MSS-CRC patients, including those with liver metastases, we have made MSS-CRC our primary development focus and look forward to advancing the Phase 2b trial,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR.

Dr. Pereg added, “We highly appreciate the continued support from our existing and new investors. Their commitment reflects confidence in the clinical potential of DSP107 and the opportunity to meaningfully improve outcomes in MSS-CRC, a disease with a significant unmet medical need, and in our team’s ability to execute as we move toward our next milestones.”

About DSP107 
DSP107, KAHR Bio’s lead drug candidate, is a first-in-class, bispecific CD47×4-1BB targeting, next-generation T-cell engager. DSP107 utilizes tumor-expressed CD47 as an anchor, selectively binding CD47 on cancer cells while sparing red blood cells, thereby overcoming the safety challenges previously seen with other CD47-directed agents. Once bound, DSP107 converts the tumor’s immune-evasion signal into a potent 4-1BB co-stimulatory activation signal, recruiting and activating CD8 cytotoxic T cells and orchestrating engagement of both the innate and adaptive immune systems to generate a coordinated anti-tumor response. This approach is particularly relevant in colorectal cancer, where more than 70% of metastatic patients develop liver metastases that commonly upregulate CD47 following earlier-line chemotherapy. Unlike prior immunotherapy approaches in MSS-CRC, which have demonstrated limited benefit due to poor immune cell infiltration and low immunogenicity, DSP107 is designed to leverage tumor CD47 overexpression to enhance immune engagement within the tumor microenvironment, transforming it from immunosuppressive to immune-responsive and enabling productive anti-tumor immunity.

About Microsatellite Stable Metastatic Colorectal Cancer
Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause of cancer mortality. Globally, CRC ranks among the top three most frequently diagnosed cancers, with approximately 1.9 million new cases and nearly 900,000 deaths annually, making it the second leading cause of cancer-related death and the third most common cancer overall. Among metastatic colorectal cancer (mCRC) cases, approximately 85–90 % are microsatellite stable (MSS). MSS-CRC is characterized by low tumor mutational burden and limited inherent immune activation, and as a result, tumors are typically unresponsive to current immunotherapies, including immune checkpoint inhibitors. Standard treatment for MSS-CRC continues to rely on cytotoxic chemotherapy, targeted agents, and VEGF inhibition. Despite advances in systemic therapy, there remains a significant unmet medical need for more effective treatment options, and ongoing research is focused on novel approaches, including immune-based and mechanism-driven combination strategies, to improve outcomes for patients with this challenging disease.

About KAHR Bio
KAHR Bio develops dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems while localizing activity within the tumor microenvironment. The Company’s multifunctional fusion proteins aim to drive coordinated and durable anticancer responses. For more information, visit us at https://kahrbio.com or contact us at [email protected] .

Media contact:
Tsipi Haitovsky
Global Media Liaison
KAHR Bio
+972-52-598-9892
[email protected]

SOURCE KAHR Medical

HONG KONG, Jan. 8, 2026 — Obita has completed its Pre-A financing round, bringing its total funding across two rounds to nearly US$30 million. The round was led by Monolith, with existing shareholders including Vision Plus Capital, Mirana Ventures and Legend Capital continuing to increase their investments. Proceeds will be used to accelerate business growth and further build Obita’s global, enterprise-grade payments infrastructure.

The company was founded by a team of seasoned industry professionals with deep experience in fintech, payments, and compliance.

SOURCE Obita

SHANGHAI, Jan. 8, 2026 — Qiming Venture Partners’ portfolio company Z.ai (formerly known as Zhipu AI), a pioneer and leader inartificial general intelligence (AGI) in China, successfully listed on the Hong Kong Stock Exchange on January 8th, 2026, Beijing time, becoming the world’s first listed large language model company.

Z.ai (02513.HK) issued shares at a price of HK$116.20 per share and opened at HK$120.00 per share with a market capitalization of HK$52.83 billion.

Qiming Venture Partners co-led Z.ai’s Series B1 financing round in early 2022, nearly a year before ChatGPT was released and sparked the global wave of large models. This funding was instrumental in supporting Z.ai to overcome R&D challenges and complete its first 100-billion-parameter large model, GLM. Qiming continued to support the company in its subsequent B2& B4funding round. Under Chapter 18C of the Hong Kong Stock Exchange, Qiming stands as Z.ai’s  experienced independent investor

Z.ai was founded in 2019 as a commercialization of technological achievements from Tsinghua University. With the mission “to make machines think like humans”, the company has remained dedicated to AGI research and development. Since its inception, Z.ai has launched China’s first 10-billion-parameter model, its first open-source 100-billion-parameter model, its first conversational model, its first multimodal model, and the world’s first device-control AI agent. It has built one of the world’s most advanced and comprehensive model portfolios and AI agent products.

GLM achieves breakthrough in full domesticization, supports over 40 domestic chips, becoming one of the most versatile model architectures in the industry. Its latest flagship model,GLM-4.7, has delivered top-tier performance among open-source models across multiple mainstream public benchmarks. In CodeArena, an authoritative coding evaluation system with global participation from a million users in blind testing, GLM-4.7 ranks first among open-source models and first among domestic models, surpassing GPT-4. Additionally, on the highly authoritative AA AI Index, the model also secured first place among open-source models and first among domestic models. The released GLM Coding Plan has already gained 150,000 users globally, establishing itself as a primary programming model solution for Chinese developers.

Today, Z.ai has grown into China’s largest independent large language model developer. Its GLM series of models are applied across various sectors including public governance, industrial manufacturing, energy and power, finance, internet, communications, consumer electronics, and education. As of September 30, 2025, Z.ai’s models had empowered over 12,000 enterprise customers, more than 80 million end-user devices, and over 45 million developers worldwide, making it the independent general-purpose large-model vendor in China with the highest number of enabled end-user devices.

Zhang Peng, CEO of Z.ai, stated: “Listing in Hong Kong represents a landmark milestone for Z.ai. Our journey—from commercializing research outcomes at Tsinghua’s labs to becoming a publicly listed company—has never strayed from our original vision: ‘to make machines think like humans’. Going public means we must shoulder even greater social responsibility and industry mission. Moving forward, Z.ai will continue to deepen our commitment to fully independent, controllable full-stack large model technology, relentlessly push the boundaries of AGI capabilities, and consistently enhance the reasoning, coding, and multimodal performance of the GLM model series. We are dedicated to building a more open and thriving AI ecosystem, empowering thousands of industries through accessible and inclusive technology, and making General Artificial Intelligence a genuine productive force for the advancement of human civilization.”

Alex Zhou, Managing Partner of Qiming Venture Partners, said, “The Z.ai team combines deep conviction in its technical roadmap with a rare ability to consistently translate frontier research into real commercial value. This dual strength—a strong belief in technology coupled with disciplined industrial execution—gives us confidence that the company will navigate the AI wave with resilience and emerge as a category leader. Z.ai’s successful IPO is not only a critical validation of China’s path in foundational AI innovation, but also sends a clear signal to the broader technology investment community: in the long run, the market recognizes and rewards teams that stay committed to frontier exploration and deep, foundational technological breakthroughs. We look forward to Z.ai building on this milestone and continuing to drive innovation in large language model technology and real-world applications, creating even greater value for the AI ecosystem.”

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai (02513.HK), Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

• Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of life

BASEL, Switzerland, Jan. 8, 2026 — TECregen, a biotechnology company pioneering thymus regeneration, today announced the successful completion of a CHF 10 million (∼EUR 10.7 million / USD 12.6 million) seed financing round. The financing was led by the Boehringer Ingelheim Venture Fund (BIVF), with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. The investment will accelerate development of TECregen’s groundbreaking thymopoietic biologics, designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen overall immune resilience.

In addition to announcing its successful seed financing, TECregen has appointed Dr. Bo Rode Hansen, Ph.D., MBA, as Chairman of the Board of Directors. Dr. Hansen is a seasoned biotech executive with over two decades of leadership experience in the pharmaceutical and biotech industry. He previously served as the CEO of Scandion Oncology A/S and was the founding President of Genevant Sciences, in addition to holding senior leadership roles at Roche and Santaris Pharma. In his role as Chairman, Dr. Hansen will help guide TECregen’s strategic growth and advance its thymus rejuvenation programs.

“I am honored to join TECregen’s Board at such a pivotal time for the company,” said Dr. Bo Rode Hansen, Chairman of TECregen. “The team’s pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune ageing and related disease. I look forward to working with the management team and our investors to accelerate the development and delivery of these transformative therapies to patients who need them most.”

“We welcome Bo as our new Chairman,” commented Filippo Oliveri, co-founder and Board Director of TECregen. “His wealth of industry expertise and proven leadership will be invaluable as we pursue our mission. Backed with the strong investor support, TECregen is well positioned to accelerate its thymus regeneration initiative and deliver innovative immune rejuvenation therapies to patients.”

“TECregen’s innovative approach to thymus regeneration firmly positions the company at the forefront of targeted biologics designed to restore immune function, with a clear trajectory toward the clinic. The ability to modulate and restore thymic function paves the way for new therapeutic opportunities across immunology, oncology, and rare diseases. We are enthusiastic to support TECregen as it advances toward clinical development,” remarked Dr. Philipp Müller, Investment Manager at BIVF.

TECregen’s groundbreaking approach places the company at the forefront of targeted biologics for immune restoration, with significant potential across multiple indications. Backed by strong investor support and the leadership of Dr. Bo Rode Hansen as Chairman, TECregen is well positioned to accelerate the development of its thymus rejuvenation programs and deliver innovative immune therapies to patients in need.

About TECregen:
TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells and achieve durable improvements in immune function. By developing a pipeline of differentiated thymopoietic biologics, TECregen aims to strengthen immune recovery following transplantation or cytotoxic therapy, promote immune health, and enhance immune surveillance against cancer, ushering in a new era of immunotherapy.

SOURCE TECregen AG

• Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries
• Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation
• Validates ViCentra’s strategy and team, following a year of significant commercial and operational milestones

UTRECHT, Netherlands, Jan. 8, 2026 — ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the second close of its Series D financing round, adding $13 million and increasing the total round to $98 million. The additional funding follows a strong year of commercial and operational progress and includes new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, alongside increased support from existing investor Innovation Industries. With this funding, ViCentra will scale manufacturing, deepen commercial execution in Germany, the Netherlands, and France, and accelerate preparations for its next-generation Kaleido insulin patch pump for U.S. market access.

This follows the successful $85 million raised in September 2025 and underscores investor confidence in ViCentra’s strategy, commercial traction, and operational performance. With this strengthened financial backing, ViCentra is well-positioned to accelerate growth and build its leadership in the expanding insulin delivery market. Its flagship product, Kaleido, stands out as the smallest, lightest, and most precise insulin patch pump in its class. Designed to feel like personal technology, it features customizable aluminum shells offered in 10 vibrant colors, allowing users to seamlessly blend medical innovation with their individual style.

“The past year has been transformative for ViCentra. This latest funding enables us to further scale our manufacturing capabilities, strengthen our commercial presence and support in Germany, the Netherlands, and France, and ensures that we remain on course for our planned U.S. market access. Our goal for 2026 is clear: convert our current high demand into satisfied users through uncompromising quality and performance and nearly triple our European user base by the end of 2026,” said Tom Arnold, Chief Executive Officer of ViCentra.

In 2025, ViCentra delivered remarkable commercial and operational gains, doubling its user base to over 4,000 and achieving strong associated revenue growth. This strong momentum, together with expanded manufacturing capacity and robust adoption in Germany—the world’s second-largest insulin pump market—as well as in the Netherlands and France, establishes a solid foundation for continued growth in 2026.

ViCentra’s leadership team, including CEO Tom Arnold, will be available for meetings with investors and strategic partners during the J.P. Morgan Healthcare Conference week in San Francisco. Additionally, Tom and the team will also be attending the LSI USA ’26 Emerging Medtech Summit in Dana Point in March. To request a meeting, please contact Optimum Strategic Communications at [email protected].

About ViCentra

ViCentra is on a mission to improve life with diabetes through empathetic innovation, simplicity, and design excellence. The company develops and manufactures the Kaleido insulin patch pump system, a flexible, discreet, and beautifully crafted alternative to traditional insulin pumps. Headquartered in Utrecht, the Netherlands, ViCentra is expanding across Europe and preparing for U.S. market entry. Its investors include Innovation Industries, Partners in Equity, Invest-NL, EQT Life Sciences, ROM Utrecht Region, Venturing Tech, Health Innovations and INKEF. More information about ViCentra can be found at www.hellokaleido.com

About Kaleido

Kaleido is redefining the category of wearable insulin delivery as the first insulin patch pump designed with the form, function, and simplicity of a lifestyle product. Compact, featherlight, and discreet, Kaleido is designed with a focus on personal technology rather than a traditional medical device. It is made from premium materials and features customizable aluminum shells in ten color options, enabling self-expression, not just glycemic control. It offers users flexibility in how and where they wear their pump, allowing people with diabetes to manage their therapy in a way that fits seamlessly into their daily lives.

It is the smallest, lightest, most precise insulin patch pump in its class—delivering advanced, automated insulin therapy through seamless integration with Diabeloop’s clinically validated hybrid closed loop algorithms, DBLG1 and DBLG2.

SOURCE ViCentra

CHICAGO, Jan. 7, 2026 — Ziegler, a national boutique investment bank, is pleased to announce the successful closing of the Series 2025 Bond Anticipation Notes (the “Series 2025 Notes”) for the benefit of The Sanctuary at Village On The Isle LLC (the “Borrower”). The Borrower was formed in 2025 to develop, own, and operate a retirement community (the “Community”) to be located on approximately 50 acres in unincorporated Sarasota County, Florida. The sole member of the Borrower is Southwest Florida Retirement Center, Inc. d/b/a Village On The Isle (“VOTI”), a Florida not-for-profit organization. VOTI owns and operates a continuing care retirement community in Venice, Florida which opened in 1982 and currently consists of 234 independent living units, 48 assisted living units, 16 memory care units and 64 licensed skilled nursing beds. The Borrower and VOTI are affiliated with the Florida-Bahamas Synod (the “Synod”) of the Evangelical Lutheran Church in America (the “ELCA”). However, neither VOTI, the Synod or the ELCA is liable for payment of principal or interest on the Series 2025 Notes.

The first phase of the Community is anticipated to consist of 130 independent living apartments and 50 independent living cottages and will be located approximately five miles from VOTI. The size of the site allows for the future growth of the Community over time. Future growth of the Community could potentially include more independent living units and/or the addition of an assisted living center. Development of future phases will depend, in part, on the market demand at the time development is being considered. Greystone has been engaged to provide development consulting services during the planning and development of the Community.

The Community will be regulated under Chapter 651, Florida Statutes. The Community is expected to offer a variety of living accommodations in a campus-like setting with residential and community buildings that are intended to blend together to create an attractive, supportive environment for its residents.

The Series 2025 Notes consist of tax-exempt Series 2025A Notes in the amount of $35,840,000 marketed to institutional investors and $2,000,000 of subordinate taxable Series 2025B Notes purchased by VOTI. Proceeds of the non-rated Series 2025 Notes will be used to provide pre-finance capital for the land acquisition, marketing and pre-development costs of the Community. It is currently anticipated that the Series 2025 Notes will be redeemed in December of 2027 with the proceeds of a long-term financing for the construction of the Community.

Doug Feller, Chief Executive Officer of VOTI, said, “We are pleased to have reached this stage of growth and could not have done so without our partnership with Ziegler. We value our strong partnership with Ziegler as we move forward with this exciting new project that supports our long-term vision.”

 Kathi Rogers, Chief Financial Officer of VOTI, said, “This milestone would not be possible without the strength of the partnerships that support Village On The Isle and share in our vision for The Sanctuary. We are thankful for Ziegler’s long-standing partnership and the collaborative efforts of our advisors, and we are especially grateful to our Board of Trustees for their strategic leadership and commitment to ensuring VOTI’s mission remains strong for generations to come.”

Rich Scanlon, Senior Managing Director, Senior Living Finance at Ziegler stated “Ziegler has had the distinct pleasure of serving as a strategic partner to VOTI since our first underwriting with them in 1985. VOTI’s management team recognizes the enormous potential of their primary market area which, combined with the quality of their product, led them to search for land upon which to build a proximate second campus. Given the pace of presales for VOTI’s 2024 expansion at their current campus, they envision strong presales for the Sanctuary with construction expected to commence in January 2028.”

Ziegler is the nation’s leading underwriter of financing for not-for-profit senior living providers. Ziegler offers creative, tailored solutions to its senior living clientele, including investment banking, financial risk management, merger and acquisition services, seed capital, FHA/HUD, capital and strategic planning as well as senior living research, education, and communication.

For more information about Ziegler, please visit us at www.Ziegler.com.

About Ziegler:
Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. It has a unique focus on healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory services, fixed income sales, underwriting and trading as well as Ziegler Credit, Surveillance and Analytics. To learn more, visit www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

SOURCE Ziegler

LG NOVA-Supported Fund and Investment Vehicle Welcomes New Investors in NovaWave Fund I Generation to Accelerate AI-First Company Creation in American West and Appalachia

LAS VEGAS, Jan. 7, 2026 — Silicon Valley–based venture capital firm NovaWave Capital announced AZ Venture Capital Inc. and Sunny Day Sports as incoming investors in the NovaWave Fund generation, further strengthening the public-private capital base supporting innovation across the United States. At CES 2026^®, together with anchor Limited Partner LG Electronics, NovaWave Capital also announced a collaboration with Arizona Commerce Authority to launch the groundbreaking “WaveX” AI venture studio that will support new ventures across the state in healthcare, energy, sports and media.

Arizona Governor, Katie Hobbs said, “Arizona is proud to welcome NovaWave Capital’s venture studio to our state, a powerful addition to our thriving innovation ecosystem. This prominent initiative reflects Arizona’s growing global importance in advanced technologies and our commitment to fostering next-gen innovations across artificial intelligence, energy, advanced manufacturing, and more.”

“With our collaborative business environment, world-class talent, and advanced technology ecosystem, Arizona offers unparalleled opportunities for startups and early-stage companies to scale and succeed,” said Sandra Watson, President and CEO of the Arizona Commerce Authority. “We are excited to partner with NovaWave Capital on the creation of a new AI venture studio and venture fund to support Arizona based companies.”

Complementing the Arizona projects are LG NOVA’s hubs in West Virginia and Silicon Valley; as well as NovaWave Capital’s presence in the Gulf region, forming a cross-regional network for technology innovation.

NovaWave Capital, created to support businesses under LG Electronics’ North America Innovation Center LG NOVA, is focused on helping to scale high growth AI companies in the energy, health and business sectors with the goal of delivering measurable, economic and industrial impact, according to NovaWave Capital’s Founding Managing Partner, “Tonton” Ali Diallo, who also founded Aurion Capital.

“Our collaboration with AZ Venture Capital Inc., Sunny Day Sports and the Arizona Commerce Authority is a testament to the vision shared by our investors and regional partners across the public and private spectrum to build and scale AI-first companies in collaboration with LG NOVA,” said Diallo. “By bridging Silicon Valley innovation with the fast-growing ecosystems of regional and international markets, we are seeking to build the next generation of AI, energy and health companies that will accelerate America’s innovation economy.”

“LG NOVA is committed to building a strong foundation for breakthrough innovation in the United States,” said Dr. Sokwoo Rhee, Executive Vice President of Innovation at LG Electronics and Head of LG NOVA. “Our collective work with NovaWave Capital allows us to identify, support, and scale impactful AI-first ventures that benefit communities and industries nationwide.”

NovaWave Capital is supported by a diverse base of investors across the corporate, institutional and government sectors, including LG Electronics, the fund’s anchor investor; the Nevada Governor’s Office of Economic Development (GOED); the WV Division of Economic Development; Sunny Day Sports; AZ Venture Capital, Aurion Capital among others.

NovaWave Capital’s venture-building and fund platform provides portfolio companies with:

• Strategic collaboration with LG NOVA, enabling commercialization pathways in the U.S. and globally
• Incubation and venture-building resources through WaveX to support rapid product development
• Regional acceleration partnerships across West Virginia, Nevada and Arizona
• Deep-sector expertise in AI, advanced energy systems, digital health and applied enterprise innovation, and
• Global commercial expansion opportunities and government and industry collaborations across Europe and the Gulf Region.

NovaWave Capital collaborates closely with a network of strategic partners in Asia, the Middle East and North America (including the U.S. states of West Virginia, Nevada and Arizona) and International NovaWave Capital collaborators from South Korea, Qatar, the UAE, Japan, and Saudi Arabia, including Samrya Group, the University of Sharjah, Marshall University, West Virginia University and the University of Nevada, Las Vegas (UNLV). Such collaborations underscore the global and cross-sector collaboration behind NovaWave Capital’s platform and its regional reach and impact across global innovation ecosystems.

NovaWave Capital is managed by Aurion Capital, a global investment group headquartered in Silicon Valley with offices in Seoul, Dubai and Abu Dhabi. Aurion Capital partners with global corporations, sovereign funds, governments and family offices to manage institutional capital, public-private partnerships and innovation programs that accelerate the growth of emerging economies across Rural America, the Southwestern United States and the Gulf. The firm is a partner of the World Economic Forum and oversees a portfolio of funds in the United States and in Abu Dhabi Global Markets.

About LG NOVA
LG NOVA, the North America Innovation Center for global innovation leader LG Electronics, is a team focused on bringing innovation from the outside to LG. LG NOVA is based in Santa Clara, Calif. The center’s mission is to fuel innovation for LG and its partners by creating and launching new ventures to become the next growth engine for LG. Learn more about LG NOVA at www.lgnova.com.

About LG Electronics USA
LG Electronics USA Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics Inc., a smart life solutions company with annual global revenues of more than $60 billion. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems and vehicle components. LG is an 11-time ENERGY STAR® Partner of the Year. www.LG.com.

About NovaWave Capital
Headquartered in Menlo Park, CA, NovaWave Capital invests in technologies with the goal of delivering measurable economic and industrial impact, and long-term capital appreciation. The firm’s investment strategy centers on scaling companies in artificial intelligence, next-generation energy and digital health, supported by public-private innovation corridors in West Virginia, the Appalachia region, Nevada, and Arizona—while leveraging commercial collaboration with LG NOVA. Learn more at www.novawavecapital.com

NovaWave Capital is a registered investment adviser (RIA).*
Registration of an investment adviser with the SEC or with any state securities authority does not imply a certain level of skill or training. This document does not constitute advice or a recommendation or offer to sell or a solicitation to deal in any security or financial product. It is provided for information purposes only and on the understanding that the recipient has sufficient knowledge and experience to be able to understand and make their own evaluation of the proposals and services described herein, any risks associated therewith and any related legal, tax, accounting or other material considerations. To the extent that the reader has any questions regarding the applicability of any specific issue discussed above to their specific portfolio or situation, prospective investors are encouraged to consult with the professional advisor of their choosing.

Media Contacts:

LG Electronics USA
Linda Quach
+1 408 903 3045
[email protected]

NovaWave Capital
[email protected]

SOURCE LG Electronics USA